Core Insights - Revolution Medicines, Inc. is set to present nine oral and poster presentations at the AACR Annual Meeting, showcasing advancements in its RAS(ON) inhibitor pipeline for RAS-addicted cancers [1][4] Presentation Highlights - New Phase 1 data for zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a plenary session, focusing on patients with previously treated KRAS G12D mutant non-small cell lung cancer [2] - Two Phase 1/2 datasets evaluating daraxonrasib, a RAS(ON) multi-selective inhibitor, will be presented, including monotherapy and combination therapy data with chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma [3] - Additional presentations will cover preclinical research on a new class of mutant-targeted catalytic RAS(ON) inhibitors, aimed at maintaining antitumor activity despite resistance [4] Presentation Details - An invited presentation titled "Targeting the Oncogenic State of RAS: Lessons from Tri-Complex Inhibitors" will be given by Dr. Mallika Singh on April 18 [6] - An oral presentation on the preliminary safety and clinical activity of zoldonrasib will be presented by Dr. Jonathan Reiss on April 19 [7] - A mini-symposium will feature daraxonrasib plus chemotherapy as a first-line treatment for metastatic pancreatic adenocarcinoma, presented by Dr. Brian Wolpin on April 21 [8] - Additional poster presentations will cover various aspects of RAS(ON) inhibitors and their effects on cancer and immune cells [10] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes multiple RAS(ON) inhibitors currently in clinical development [12]

Core Insights - The most significant event anticipated for the year is the readout of the RASolute 302 trial, which compares daraxonrasib monotherapy to chemotherapy in previously treated pancreatic cancer patients, expected in the first half of the year [1] Group 1: Clinical Trials - A total of 5 Phase III studies have been initiated, with 4 focused on pancreatic cancer, which are expected to progress in enrollment this year [2] - Previous data from a small cohort indicated response rates for daraxonrasib monotherapy and daraxonrasib plus chemotherapy in first-line pancreatic cancer [2]

Summary of Revolution Medicines FY Conference Call Company Overview - **Company**: Revolution Medicines (NasdaqGS: RVMD) - **Industry**: Biotechnology, specifically focused on targeted therapies for RAS-driven cancers, particularly pancreatic cancer Key Value Creation Events - The most significant upcoming event is the readout of the **RASolute 302 trial** for daraxonrasib in previously treated pancreatic cancer, expected in the first half of 2026 [3][4] - Five Phase 3 studies are underway, with four focused on pancreatic cancer [3] Trial Insights - The RASolute 302 trial design includes a core cohort of patients with G12 mutations, which represent about 85% of pancreatic cancer cases [7] - Two potential analyses will be conducted: one for the core cohort and another including all pancreatic cancer patients [8] - Possible outcomes include passing progression-free survival (PFS) and overall survival (OS) statistical significance, with varying implications for data presentation [9][10] Treatment Strategy - Revolution Medicines emphasizes the importance of RAS suppression across all treatment lines, asserting that RAS-driven characteristics persist regardless of treatment history [12][13] - Initial data from previously treated pancreatic cancer patients show promising response rates compared to chemotherapy [14] Regulatory and Commercialization Plans - The company is prepared for a swift NDA submission following positive trial results, having established manufacturing and regulatory processes [20][21] - A National Priority Voucher from the FDA is expected to expedite the review process [20] - An educational campaign, "Expect RAS," aims to inform practitioners about RAS-driven pancreatic cancer [22] Enrollment and Patient Access - Enrollment for the first-line trial is anticipated to be rapid once operational processes are complete, with high demand for daraxonrasib from patients [28][29] - The trial design includes a control arm, which may lead to patient dropouts if they prefer alternative treatments [33][34] Importance of Overall Survival - Establishing OS is crucial for regulatory approval and market uptake, with the company aiming to demonstrate survival benefits in both first and second-line treatments [40][41] Ongoing and Future Trials - Multiple trials are being conducted for different RAS inhibitors, including zoldonrasib, which is well-tolerated and shows promise in combination with chemotherapy [54] - The company is exploring various treatment combinations to address the diverse needs of pancreatic cancer patients [53] Market Considerations - There is skepticism regarding the commercial potential of later-line lung cancer therapies, but Revolution Medicines believes their RAS inhibitors can significantly improve patient outcomes compared to existing standards of care [69] Colorectal Cancer Developments - The company is optimistic about finding a path forward in colorectal cancer but has not provided specific timelines or details on upcoming data [73] This summary encapsulates the key points discussed during the Revolution Medicines FY Conference Call, highlighting the company's strategic focus on RAS-driven cancers and its plans for upcoming trials and regulatory submissions.

Core Insights - Revolution Medicines, Inc. (NASDAQ:RVMD) is recognized as a promising investment in the cancer sector, particularly due to its advancements in RAS(ON) inhibitors [1][5] Financial Performance - The company reported a net loss of $364.9 million in Q4 2025, nearly doubling from $194.6 million in the same quarter of the previous year [4] - The full-year net loss for 2025 reached $1.1 billion, compared to $600.1 million in 2024 [4] - Research and development expenses surged to $294.9 million in Q4 2025 from $188.1 million in Q4 2024, with total R&D expenses for the year amounting to $987.3 million, up from $592.2 million in 2024 [4] Clinical Developments - The company is currently enrolling patients in the US for a Phase 3 trial of daraxonrasib in Non-Small Cell Lung Cancer (NSCLC) [2] - A pivotal readout from the RASolute 302 trial for daraxonrasib in pancreatic cancer is expected in the first half of 2026, marking a significant milestone for the company's RAS(ON)-targeting strategy [3] - Zoldonrasib has demonstrated a highly differentiated safety and tolerability profile as a G12D-selective covalent inhibitor [2] Market Position - Revolution Medicines focuses on targeted therapies for RAS-addicted cancers, which account for approximately 30% of new cancer diagnoses [5]

Company Overview - Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company focused on developing novel targeted therapies for cancer treatment [4] Investment Potential - Revolution Medicines has been initiated with an Outperform rating and a price target of $140 by Evercore ISI, indicating strong buy potential [1] - The company is expected to launch daraxonrasib, which is seen as a potential breakthrough in oncology, with key Phase 3 data for pancreatic cancer anticipated in the first half of 2026 [1] Financial Performance - As of December 31, 2025, Revolution Medicines reported cash, cash equivalents, and marketable securities totaling $2.0 billion [2] - Research and development expenses for Q4 were $294.9 million, up from $188.1 million in the previous year, attributed to increased clinical trial and manufacturing costs for daraxonrasib, zoldonrasib, and elironrasib, as well as higher personnel-related expenses [3]

Core Insights - Revolution Medicines (RVMD) reported a Q4 2025 loss of $1.86 per share, which is wider than the Zacks Consensus Estimate of a loss of $1.56, and a significant increase from a loss of $1.12 in the same quarter last year [1][7] - The company has no approved products and did not generate any revenues in 2025 [5][8] - RVMD's stock fell 5% in after-market trading following the earnings report, despite a year-to-date increase of 30%, outperforming the industry growth of 10% [1][2] Financial Performance - Research and development expenses for Q4 2025 were $294.9 million, reflecting a nearly 57% year-over-year increase, driven by higher costs for clinical studies and manufacturing [3] - General and administrative expenses reached $66.7 million, up more than 136% year-over-year, primarily due to increased commercial preparation activities and employee-related expenses [3] - For the full year 2025, the company reported a loss of $5.95 per share, wider than the $3.58 loss from the previous year [8] Cash Position - As of December 31, 2025, Revolution Medicines had cash and cash equivalents of $2 billion, an increase from $1.9 billion as of September 30, 2025 [4] 2026 Guidance - RVMD expects operating expenses for 2026 to be between $1.6 billion and $1.7 billion, which includes non-cash stock-based compensation expenses of $180-$200 million [9] Pipeline Developments - The company is advancing daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, into multiple late-stage studies for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) [10][12] - The RASolute 302 study is assessing daraxonrasib in second-line metastatic PDAC, while the RASolute 303 study is evaluating its efficacy in the first-line setting [11] - RVMD has initiated the phase III RASolute 305 study to evaluate the combination of zoldonrasib with chemotherapy in first-line PDAC patients [14] Strategic Collaborations - To enhance its pipeline, Revolution Medicines has entered into collaborations with companies like Summit Therapeutics and Tango Therapeutics to evaluate combinations of its RAS(ON) inhibitors with their drugs [15] - A recent collaboration with Bristol Myers Squibb aims to evaluate daraxonrasib in combination with navlimetostat for certain pancreatic cancer patients [16]

Market Overview - U.S. equity markets reached new all-time highs in Q4 2025, with the S&P 500 Index rising 2.66% and the Bloomberg U.S. Aggregate Bond Index increasing by 1.10% [1] - The U.S. economy showed resilience, although consumer confidence deteriorated toward year-end, raising concerns about future spending and the labor market [1] Fund Performance - The Aristotle Growth Equity Fund (Class I-2) returned 0.95%, underperforming the Russell 1000 Growth Index's 1.12% [1] - Poor security selection in the information technology and consumer discretionary sectors detracted from performance, while positive contributions from healthcare and industrials improved relative performance [1] Company Highlight: Revolution Medicines, Inc. - Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company focused on developing therapies for RAS-addicted cancers [2][3] - As of February 25, 2026, Revolution Medicines, Inc. stock closed at $103.24 per share, with a one-month return of 5.13% and a 52-week gain of 164.18% [2] - The company has a market capitalization of $19.958 billion [2] - Revolution Medicines is developing RAS(ON) inhibitors to block growth signals from RAS proteins, with main drugs including Daraxonrasib, Elironrasib, and Zoldonrasib already in clinical trials [3] - The company is also working on bringing a new drug, RMC-5127, into trials soon and developing targeted treatments for other types of RAS mutations [3]

Financial Data and Key Metrics Changes - The company ended Q4 2025 with $2.03 billion in cash and investments, having entered a strategic partnership with Royalty Pharma that provided access to up to $2 billion in committed capital [21] - R&D expenses for Q4 2025 were $294.9 million, up from $188.1 million in Q4 2024, primarily due to increased clinical trial and manufacturing expenses [21][22] - G&A expenses for Q4 2025 were $66.7 million, compared to $28.2 million in Q4 2024, driven by commercial preparation activities and increased personnel-related expenses [22] - The net loss for Q4 2025 was $364.9 million, compared to $194.6 million in Q4 2024, attributed to higher operating expenses [22][23] - Full year 2026 GAAP operating expenses are expected to be between $1.6 billion and $1.7 billion, reflecting the expansion of clinical development programs [24] Business Line Data and Key Metrics Changes - The company has advanced its pipeline with four novel investigational drugs targeting major oncogenic RAS drivers, including daraxonrasib, elironrasib, zoldonrasib, and RMC-5127 [8][9] - There are currently eight ongoing or planned phase 3 registrational trials, with over 2,500 patients having received one or more RAS(ON) inhibitors [8] Market Data and Key Metrics Changes - The company is focusing on pancreatic cancer, where over 90% of cases are RAS-driven, and has multiple registrational trials underway or planned for 2026 [9][10] - The FDA has granted daraxonrasib Breakthrough Therapy Designation, highlighting its potential to address significant unmet needs in pancreatic cancer [10] Company Strategy and Development Direction - The company aims to revolutionize treatments for RAS-addicted cancers through innovative targeted medicines and has established a strong operational foundation for a successful commercial launch [7][20] - The company is committed to advancing its RAS(ON) inhibitor pipeline and exploring novel approaches to overcome RAS-driven drug resistance [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of their pipeline to transform treatment standards for difficult-to-treat cancers, with key milestones expected in 2026 [26] - The company is preparing for its first commercial launch, initially focused on the U.S. market, and has made strategic hires to support this effort [20] Other Important Information - The company is exploring collaborations with other firms to evaluate RAS(ON) inhibitors in combination with new targeted therapies [16][17] - The company has initiated a clinical collaboration with Bristol Myers Squibb to evaluate daraxonrasib in combination with navlimetostat in pancreatic cancer patients [17] Q&A Session Summary Question: Plans to advance daraxonrasib combination in first-line non-small cell lung cancer - Management confirmed a high commitment to continue developing daraxonrasib in lung cancer, particularly in the first line, with ongoing dose optimization and efficacy testing [30][31] Question: Efficacy measure for the second-line PDAC trial - Management indicated that the study is powered for overall survival (OS) and progression-free survival (PFS), but no specific expectations could be provided at this time [36] Question: Impact of daraxonrasib use in first-line studies on OS outcomes - Management acknowledged potential complications with crossover from the control arm but emphasized that they expect to establish significant momentum before FDA review [41][42] Question: Ongoing partnered collaborations and decision-making for late-stage trials - Management explained that decisions about advancing into late-stage trials will be data-driven, considering the emerging combination data and the broader landscape of ongoing trials [48] Question: Treatment beyond progression in PDAC - Management noted that while treatment beyond progression is not permitted in the RASolute 302 study, they encourage evaluation of this possibility in other studies [78]

Financial Data and Key Metrics Changes - The company ended Q4 2025 with $2.03 billion in cash and investments, and entered into a strategic partnership with Royalty Pharma, providing access to up to $2 billion in committed capital [22][24] - R&D expenses for Q4 2025 were $294.9 million, up from $188.1 million in Q4 2024, primarily due to increased clinical trial and manufacturing expenses [22][23] - G&A expenses for Q4 2025 were $66.7 million, compared to $28.2 million in Q4 2024, driven by commercial preparation activities and personnel-related expenses [23] - The net loss for Q4 2025 was $364.9 million, compared to $194.6 million in Q4 2024, attributed to higher operating expenses [23][24] - Full year 2026 GAAP operating expenses are expected to be between $1.6 billion and $1.7 billion, including estimated non-cash stock-based compensation of $180 million to $200 million [25][26] Business Line Data and Key Metrics Changes - The company has advanced its RAS(ON) inhibitor pipeline, which includes four investigational drugs targeting major oncogenic RAS drivers [8][10] - The most advanced program, daraxonrasib, has shown an unprecedented clinical profile across RAS mutations and is currently being evaluated in three randomized registrational studies in pancreatic cancer [10][11] - Zoldonrasib, a G12D selective inhibitor, has shown a high disease control rate of 95% in initial data from patients with metastatic pancreatic cancer [12][13] Market Data and Key Metrics Changes - The company is focusing on pancreatic cancer, non-small cell lung cancer, and colorectal cancer, with ongoing and planned registrational trials in these areas [14][17] - Approximately 90% of pancreatic cancers are RAS-driven, highlighting the need for RAS-targeted therapies [9] - The company is also exploring collaborations with other firms to evaluate RAS(ON) inhibitors in combination with new targeted therapies [18] Company Strategy and Development Direction - The company aims to revolutionize treatments for patients with RAS-addicted cancers through innovative targeted medicines [7][8] - There is a strong commitment to advancing clinical development programs and preparing for commercialization, particularly in the U.S. market [21][27] - The company is investing in new approaches to overcome RAS-driven drug resistance and extend the clinical benefit of RAS(ON) inhibitors [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of their pipeline to transform treatment standards for difficult-to-treat cancers [27] - The company is well-positioned for substantial impact in 2026, with key milestones across clinical programs and preparations for the first commercial launch [27][28] Other Important Information - The company has received Breakthrough Therapy Designation for daraxonrasib and zoldonrasib, indicating their potential to address significant unmet needs in cancer treatment [10][15] - The company is preparing to initiate a new class of RAS(ON) inhibitors designed to overcome drug resistance [19][20] Q&A Session Summary Question: Plans to advance daraxonrasib combination in first-line non-small cell lung cancer - Management confirmed a high commitment to continue developing daraxonrasib in lung cancer, with ongoing dose optimization and efficacy testing [30][32] Question: Efficacy measure for the second-line PDAC trial - Management indicated that the study is powered for overall survival (OS) and progression-free survival (PFS), but could not provide specific expectations at this time [36][38] Question: Ongoing studies in first-line pancreatic cancer - Management acknowledged excitement around daraxonrasib and discussed the potential impact of its use in first-line studies on OS outcomes [41][42] Question: Collaboration with Bristol's PRMT5 inhibitor - Management explained the rationale for combining RAS inhibitors with multiple PRMT5 inhibitors and emphasized a data-driven approach for advancing into late-stage trials [46][49] Question: RMC-055 and its potential role - Management noted that RMC-055 addresses reactivation of the RAS pathway rather than secondary mutations and will provide more clarity at upcoming scientific meetings [89][90] Question: Commercialization preparations - Management highlighted the progress in launch readiness, with experienced teams in place across various functions and regions [95][96]

Financial Data and Key Metrics Changes - The company ended Q4 2025 with $2.03 billion in cash and investments, and entered a strategic partnership with Royalty Pharma, providing access to up to $2 billion in committed capital [19][22] - R&D expenses for Q4 2025 were $294.9 million, up from $188.1 million in Q4 2024, primarily due to increased clinical trial and manufacturing expenses [19][20] - G&A expenses for Q4 2025 were $66.7 million, compared to $28.2 million in Q4 2024, driven by commercial preparation activities [21] - The net loss for Q4 2025 was $364.9 million, compared to $194.6 million in Q4 2024, attributed to higher operating expenses [21][22] - Full year 2026 GAAP operating expenses are expected to be between $1.6 billion and $1.7 billion, reflecting the expansion of clinical development programs [23] Business Line Data and Key Metrics Changes - The company advanced its RAS(ON) inhibitor pipeline, which includes four investigational drugs targeting major oncogenic RAS drivers [5][6] - The most advanced program, daraxonrasib, received Breakthrough Therapy Designation from the FDA, indicating its potential to address significant unmet needs in pancreatic cancer [8][12] - The company has initiated multiple registrational studies for daraxonrasib in pancreatic cancer, including RASolute 302, 303, and 304 [9][10] Market Data and Key Metrics Changes - The company is focusing on pancreatic cancer, non-small cell lung cancer, and colorectal cancer, with ongoing and planned registrational trials in these areas [11][12][15] - Approximately 90% of pancreatic cancers are RAS-driven, highlighting the need for targeted therapies [6][12] - The company is also exploring combination therapies with PRMT5 inhibitors and other novel agents to enhance treatment efficacy [16][19] Company Strategy and Development Direction - The company aims to revolutionize treatments for RAS-addicted cancers through innovative targeted medicines and has established a strong operational foundation for commercialization [4][18] - The strategy includes advancing clinical programs, preparing for the first commercial launch, and investing in new approaches to overcome drug resistance [17][18] - The company is committed to building a global oncology enterprise and has made key strategic hires to support this goal [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of their pipeline to transform treatment standards for difficult-to-treat cancers [25] - The company anticipates 2026 to be a year of substantial impact, with key milestones across clinical programs and preparations for commercialization [25] - Management acknowledged the importance of partnerships and ongoing support from healthcare providers, patients, and investors [25] Other Important Information - The company is preparing to initiate a new class of RAS(ON) inhibitors designed to overcome drug resistance, with plans for clinical development later in the year [17] - The company is also evaluating the potential of treating beyond progression in clinical trials, particularly in pancreatic cancer [75] Q&A Session Summary Question: Plans to advance daraxonrasib combination in first-line non-small cell lung cancer - Management confirmed a commitment to continue developing daraxonrasib in lung cancer and will provide more information as it becomes available [28][29] Question: Efficacy measure for second-line PDAC trial - Management stated that the study is powered for overall survival (OS) and will provide interim data as appropriate [34] Question: Ongoing studies in first-line pancreatic cancer - Management discussed the potential impact of daraxonrasib on second-line indications and the importance of demonstrating OS in studies [38][40] Question: Collaboration with PRMT5 inhibitors - Management explained the rationale for combining RAS inhibitors with PRMT5 inhibitors and the decision-making process for advancing into late-stage trials [44][45] Question: Commercialization preparations - Management highlighted the progress in launch readiness and the establishment of a strong leadership team for commercialization efforts [94][95] Question: Treatment beyond progression in PDAC - Management clarified that treatment beyond progression is not permitted in the RASolute 302 study but encouraged in future studies [77]